The Benzophenanthridine Alkaloid Fagaronine Induces Erythroleukemic Cell Differentiation by Gene Activation

Abstract

Fagaronine, a benzophenanthridine alkaloid from Fagara zanthoxyloides Lam. (Rutaceae), has been tested on the erythroleukemic cell line K562 in order to explain some previous results on cell differentiation. In this study we showed that fagaronine induces a significant hemoglobinization of the human erythroleukemic cell line K562. This hemoglobin synthesis was accompanied by a strong increase of erythroid mRNA expression such as γ- and α-globin, and PBGD, an enzyme of heme synthesis. In addition, the Epo-R transcripts were also stimulated indicating that cells are engaged in a maturation process. Both transcription factors GATA-1 and NF-E2, which play an important role in the regulation of genes involved in the erythroid differentiation, were also transcriptionally up-regulated. To elucidate the possible role of GATA-1 in the FAG-induced differentiation of K562 cells, we transfected reporter constructs containing regulatory regions of erythroid genes encompassing GATA-1 binding sites. After 48 hours of treatment, FAG stimulated the EPO-R and γ-globin promoters by 2- to 3-fold and the promoter/enhancer region of GATA-1 gene by 3.2-fold. A mutation within the GATA-1 binding sites strongly decreased the promoter activation induced by FAG. Taken together, our results represent a demonstration that FAG exerts its differentiating activity by a specific activation of the regulating GATA-1 regions of genes involved in the erythroid phenotype expression.

Abbreviations

ACLA:aclacinomycin

FAG:fagaronine

PBGD:porphobilinogene deaminase

EPO-R:erythropoietin receptor

GAPDH:glyceraldehydes 3-phosphate dehydrogenase

FCS:fetal calf serum

Key words

Fagaronine - K562 cell differentiation - leukemia - erythroid gene expression - GATA-1 transcription factor

References

• 1 Reiss M, Gamba-Vitalo C, Sartorelli A C. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms.  Cancer Treat Rep. 1986;  70 201-18
• 2 Degos L, Dombret H, Chomienne C, Daniel M T, Micléa J M, Chastang C, Castaigne S, Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.  Blood. 1995;  85 2643-53
• 3 Trentesaux C, Ngo Nyoung M, Aries A, Morceau F, Ronchi A, Ottolenghi S, Jardillier J C, Jeannesson P. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells.  Leukemia. 1993;  7 452-7
• 4 Aries A, Trentesaux C, Ottolenghi S, Jardillier J C, Jeannesson P, Doubeikovski A. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells.  Blood. 1996;  87 2885-90
• 5 Morceau F, Chenais B, Gillet R, Jardillier J C, Jeannesson P, Trentesaux C. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.  Cell Growth Diff. 1996;  7 1023-9
• 6 Comoë L, Jeannesson P, Trentesaux C, Desoize B, Jardillier J C. The antileukemic alkaloid fagaronine and the human K 562 leukemic cells: effects on growth and induction of erythroid differentiation.  Leuk Res. 1987;  11 445-51
• 7 Messmer W M, Tin-WA M, Fong H HS, Bevelle C, Farnsworth N R, Abraham D J, Trojanek J. Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae).  J Pharm Sci. 1972;  61 1858-9
• 8 Sethi V S. Inhibition of mammalian and oncornavirus nucleic acid polymerase activities by alkoxybenzophenantridine alkaloids.  Cancer Res. 1976;  36 2390-5
• 9 Pezzuto J M, Antosiak S K, Messmer W M, Slaytor M B, Honig G R. Interaction of the antileukemic alkaloid, 2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c]phenanthridine (fagaronine), with nucleic acids.  Chem Biol Interact. 1983;  43 323-39
• 10 Casiano Torres C A, Baez A. Effects of the antitumor drugs 3-nitrobenzothialozo[3,2-a]quinolium and fagaronine on nucleic acid and protein synthesis.  Biochem Pharmacol. 1986;  35 679-85
• 11 Larsen A K, Grondard L, Couprie J, Desoize B, Comoë L, Jardillier J C, Riou J .F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II.  Biochem Pharmacol. 1993;  46 1403-12
• 12 Fleury F, Sukhanova A, Ianoul A, Devy J, Kudelina I, Duval O, Alix A J, Jardillier J C, Nabiev I. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding.  J Biol Chem. 2000;  275 3501-9
• 13 Tan G T, Lee S, Lee I S, Chen J, Leitner P, Bersterman J M, Kinghorn A D, Pezzuto J M. Natural-product inhibitors of human DNA ligase I.  Biochem J. 1996;  314 993-1000
• 14 Sethi M L. Inhibition of reverse-transcriptase activity by benzophenantridine alkaloids.  J Nat Prod. 1979;  42 187-96
• 15 Tan G T, Pezzuto J M, Kinghorn A D, Hughes S H. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.  J Nat Prod. 1991;  54 143-54
• 16 Sorensen B S, Jensen P B, Sehested M, Jensen P S, Kjeldsen E, Nielsen O F, Alsner J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I.  Biochem Pharmacol. 1994;  47 2105-10
• 17 Leonard M, Brice M, Engel J D, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation.  Blood. 1993;  82 1071-9
• 18 Privitera E, Schiro R, Longoni D, Ronchi A, Rambaldi A, Bernasconi S, Ottolenghi S, Masera G, Biondi A. Constitutive expression of GATA-1, EPOR, α-globin, and γ-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia.  Blood. 1995;  86 323-8
• 19 Gillet R, Devemy E, Dupont C, Billat C, Jeannesson P, Trentesaux C. Evidence of the role of protein kinase C during aclacinomycin induction of erythroid differentiation in K 562 cells.  FEBS Lett. 1999;  454 331-4
• 20 Warrell R PJ, He L, Richon V, Calleja E, Pandolfi P P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.  J Natl Cancer Inst. 1998;  90 1621-5
• 21 Mann K K, Rephaeli A, Colosimo A L, Diaz Z, Nudelman A, Levovich I, Jing Y, Waxman S, Miller Jr W H. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.  Mol Cancer Res. 2003;  1 903-12